Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Inhibrx Biosciences, Inc.
13G
INBX · 45720N103
|
5.3% |
8/14/2026
Event 6/30/2026
|
|||
|
Cardinal Infrastructure Group Inc.
13G/A
Amendment 1
CDNL · 14154A102
|
2.9% |
5/15/2026
Event 3/31/2026
|
|||
|
Jiuzi Holdings, Inc.
13G
JZXN · G51400151
|
0% |
2/17/2026
Event 2/10/2026
|
|||
| Schonfeld Strategic Advisors LLC | 0% | ||||
| Sassicaia Capital Advisers LLC | 0% | ||||
|
Mersana Therapeutics, Inc.
13G/A
Amendment 1
MRSN · 59045L106
|
0% |
2/17/2026
Event 12/31/2025
|
|||
|
Cardinal Infrastructure Group Inc.
13G
CDNL · 14154A102
|
8.6% |
2/17/2026
Event 12/31/2025
|
|||
|
Mersana Therapeutics, Inc.
13G
MRSN · 59045L106
|
5.5% |
11/14/2025
Event 9/30/2025
|
|||
|
Mersana Therapeutics, Inc.
13G/A
Amendment 1
MRSN · 59045L106
|
4.6% |
8/14/2025
Event 6/30/2025
|
|||
|
Skye Bioscience, Inc.
13G/A
Amendment 1
SKYE · 83086J200
|
3.6% |
8/14/2025
Event 6/30/2025
|
|||
|
Fate Therapeutics, Inc.
13G/A
Amendment 1
FATE · 31189P102
|
0.8% |
8/14/2025
Event 6/30/2025
|
|||
|
Mersana Therapeutics, Inc.
13G
MRSN · 59045L106
|
6.1% |
5/15/2025
Event 3/31/2025
|
|||
|
Terns Pharmaceuticals, Inc.
13G/A
Amendment 2
TERN · 880881107
|
4.9% |
5/15/2025
Event 3/31/2025
|
|||
|
Skye Bioscience, Inc.
13G
SKYE · 83086J200
|
5.2% |
5/15/2025
Event 3/31/2025
|
|||
|
Fate Therapeutics, Inc.
13G
FATE · 31189P102
|
6.8% |
5/15/2025
Event 3/31/2025
|
|||
|
Applied Therapeutics, Inc.
13G/A
Amendment 1
APLT · 03828A101
|
3.3% |
5/15/2025
Event 3/31/2025
|
|||
|
Reviva Pharmaceuticals Holdings, Inc.
13G/A
Amendment 1
RVPH · 76152G100
|
2.8% |
2/14/2025
Event 12/31/2024
|
|||
|
Applied Therapeutics, Inc.
13G
APLT · 03828A101
|
7.5% |
2/14/2025
Event 12/31/2024
|
|||
|
Terns Pharmaceuticals, Inc.
13G/A
Amendment 1
TERN · 880881107
|
6.2% |
2/14/2025
Event 12/31/2024
|
|||